T1	p 137 170	after major gynecologic surgery .
T2	p 349 446	360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) . Subjects
T3	p 700 717	patients and four
T4	p 921 927	severe
T5	i 22 76	prophylactic ondansetron , droperidol , perphenazine ,
T6	i 81 95	metoclopramide
T7	i 211 222	intravenous
T8	i 229 274	. ) ondansetron , droperidol , perphenazine ,
T9	i 279 293	metoclopramide
T10	i 353 356	ASA
T11	i 405 437	abdominal hysterectomy ( TAH ) .
T12	i 474 478	i.v.
T13	i 488 587	ondansetron 4 mg , droperidol 1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or placebo prior
T14	i 665 679	metoclopramide
T15	i 733 744	ondansetron
T16	i 855 865	droperidol
T17	i 1069 1086	antiemetic rescue
T18	i 1148 1161	. ondansetron
T19	i 1173 1185	droperidol (
T20	i 1195 1211	and perphenazine
T21	i 1255 1262	placebo
T22	i 1285 1299	Metoclopramide
T23	i 1327 1370	ondansetron , droperidol , and perphenazine
T24	i 1433 1447	. perphenazine
T25	i 1500 1512	perphenazine
T26	i 1565 1570	TAH .
T27	o 117 136	nausea and vomiting
T28	o 617 628	Hypotension
T29	o 755 784	profound systolic hypotension
T30	o 881 882	.
T31	o 910 961	developing severe nausea , retching , or vomiting ,
T32	o 973 995	severe emetic sequelae
T33	o 1087 1088	.
T34	o 1112 1118	number
T35	o 1457 1472	of side effects